Abiopharma

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

New Form 6-K - Clearmind Medicine Inc. Filed: 2025-06-23 AccNo: 0001213900-25-056417 Size: 25 KB

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

New Form 8-K - CorMedix Inc. Filed: 2025-06-23 AccNo: 0001213900-25-056415 Size: 225 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Forte Biosciences, Inc. Filed: 2025-06-23 AccNo: 0001193125-25-144174 Size: 28 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - FRACTYL HEALTH, INC. Filed: 2025-06-23 AccNo: 0000950170-25-088710 Size: 267 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 10-K - Grace Therapeutics, Inc. Filed: 2025-06-23 AccNo: 0001140361-25-023259 Size: 8 MB

New Form 425 - Carisma Therapeutics Inc. Filed: 2025-06-23 AccNo: 0001104659-25-061398 Size: 1 MB

New Form 8-K - Carisma Therapeutics Inc. Filed: 2025-06-23 AccNo: 0001104659-25-061397 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data ShowingRevita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Johnson & Johnson - IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases